Swedencare's Record Quarter Is Also Its Credibility Breaking Point

A second straight pre-close-then-miss, a 2% organic print, and a CEO exit — while Pharma and Vetio South quietly build the next machine

SECARE.ST · Earnings Call · 2026-10-21

Two Percent, and a CEO Handing Over the Keys

Swedencare's Q3 2026 was, by its CFO's own framing, the best quarter in company history on both sales and profit: SEK 732 million of revenue, up 3% reported and 9% sequentially, with a gross margin of 59.2% and operational EBITDA of SEK 150 million. And yet the call was a wake. Organic growth landed at 2% against the 7% the CEO had publicly expected three weeks before quarter-end. “2% is not where we want to be, but we understand the reasons behind the shortfall” — Håkan Lagerberg, CEO · 2026-10-21, Håkan Lagerberg said — then conceded that the full-year double-digit organic target would not be met, since closing the gap would require north of 20% growth in Q4 alone. Worse than the number was the pattern. Three weeks before the print, management had guided to something like Q2's 7%. Instead, September came in flat with July. An SQF inspection that passed but ran days long and required immediate remediation, a late-quarter slip in European veterinary orders, and internal supply chain failures that starved the group's own Amazon sales all cost the final weeks of the quarter. Management declined to size any of it.

The Forecast Is the Story, Not the Growth

The Q&A turned on one question, and it deserves to be quoted at length because it frames the whole report:

In Q2, you said that you would build more margin when presenting expectations, yet at the pre-close, which was 2/3 into the quarter, you guided for organic growth similar to Q2 7%, and the outcome was 2%. So what has changed in your forecasting, and why should we trust the forecasting going forward when there is very little room for error?
Speaker 4, Analyst · 2026-10-21

This is the second consecutive quarter of the same failure mode. In July, a large North American order slipped from June into the following quarter, and the analyst response then was already pointed: “there has been some volatile quarters, and this isn't the first time where revenues are being delayed further into the year” — Adela Dashian, Analyst · 2026-07-22. Håkan's answer then was that the company had been “working hard with forecasting and have monthly updates” — Håkan Lagerberg, Chief Executive Officer · 2026-07-22 — and now, one quarter later, the same admission: “I am very disappointed, and I am sorry for the forecast given” — Håkan Lagerberg, CEO · 2026-10-21. The forecasting keyword has migrated from apologetic footnote to the central unresolved item. Against that backdrop, the announced CEO transition lands differently than a routine succession. Lagerberg framed it as timing — twelve years in the seat, a wish for a better handover setting. But it arrives in the same release as the miss, and the analyst pressed directly on whether he was aligned with the board. His answer was that when the new CEO arrives, “we will have seen one or two better quarters than we have delivered in 2026” — Håkan Lagerberg, CEO · 2026-10-21. That is a target, not a delivery.

Where the Growth Engine Actually Is

The genuine bull case sits outside the troubled segment. Europe grew 13% reported and 11% organically to SEK 184 million, now a quarter of the group, led by UK online plus Germany and Spain, with export sales already exceeding the whole of 2025 in nine months on China and Chile. ProDen PlaqueOff grew above 30% overall and 33% in North America — the one brand working everywhere. Production also delivered 11% organic to SEK 142 million, and this is where the call's forward-looking weight went. The Pharma segment — Vetio North in Montreal plus Summit Vet — now has an FDA pre-approval inspection with no observations at its Rx facility, production slated for 2027, and Summit Vet launched what management calls the first pharmaceutical soft chew on the UK market, with prednisolone and fluoxetine behind gabapentin. And Vetio South, the name that rocketed to the top of this quarter's keyword set, is being rebuilt into three plants under one roof: soft chews, pet treats (injection-molding machines received this month, ramp in Q1 2027), and GMP-grade non-sterile Rx liquids. Management frames the post-expansion addressable market at $12 billion versus roughly $9 billion today.

What Management Stopped Saying

The most revealing change is a deletion. Through Q1 and Q2 2026, the transcript was dominated by MAP pricing, rogue sellers, Buy Box clawbacks and Amazon marketing spend — the language of a company fighting a channel war. In Q3, those themes vanish from the top of the stack. What replaced them: large order timing, veterinary market softness, and internal logistics. That shift is either evidence the Amazon problem is genuinely fixed — the CFO says the US Amazon return improved into August and September — or evidence that the story has been re-potted so the blame sits on inspections and freight rather than demand. The NaturVet brand also falls out of the top keywords even as North America remains 56% of revenue and the explicit number-one priority. The stated cause of the -4% organic North American print is a brutally simple comparison: Q3 2025 was the Walmart load-in. The brand is now turnaround rhetoric without turnaround numbers, with management explicitly warning it does not expect double-digit growth in the segment in Q4 and would be happy just to be back in positive territory. The mechanics underneath are not alarming. Net debt to EBITDA is 3.0x, nudged by the Summit Vet earn-out entering the twelve-month window, but absolute debt fell SEK 70 million in the quarter. Cash conversion improved to 64%, though inventory and receivables are still inflating. Margins held: gross at 59.2%, operational EBITDA at 20.5% versus 21.7%, with the CFO attributing the majority of the compression squarely to North American volume deleverage.

The Setup Into 2027

Nothing in this quarter argues the business is broken; plenty argues that its communication function is. Europe and Production both compound at 11%, Pharma has a 2027 launch queue, and Vetio South converts a challenged vet-channel site into a retail-and-online-capable one. None of that requires new capital or new markets — it requires delivery. The tell is the February 2026 call, when the same CEO promised the same remedy after a Q4 2025 cost debacle: “And the way to rebuild that trust is that we show a couple of quarters with improved margins and improved EBITDA” — Hakan Lagerberg, CEO · 2026-02-12. Margins did improve. Trust did not, because the miss moved from the cost line to the revenue line. A new CEO inherits a genuinely improving asset base and a market that will discount every guidance until two clean quarters are printed. The first test is Q4, where management has aimed at double digits and, wisely this time, refused to quantify the caveats.